Gilead and Xilio recently announced an exclusive license agreement to develop and commercialize Xilio’s XTX301, a Phase 1 tumor-activated IL-12 program. Waltham, Massachusetts-based Xilio Therapeutics is a clinical-stage biotechnology company that is developing tumor-activated immuno-oncology therapies. It is using a tumor-activated platform to build tumor-activated molecules, including antibodies, cytokines, bispecifics and cell engagers. Each of…
Gilead wins ruling in battle against alleged counterfeiters in HIV drug case
A federal judge ruled against two defendants accused of selling counterfeit HIV medications, denying their motions to lift existing asset freezes obtained by pharmaceutical company Gilead Sciences in the ongoing lawsuit. Judge Ann M. Donnelly of the United States District Court for the Eastern District of New York converted the temporary asset freezes into preliminary…
Gilead gains ground in HIV drug counterfeit litigation
A New York federal judge has frozen the assets of several individuals and entities for their alleged role in distributing counterfeit versions of Gilead Science’s (Nasdaq:GILD) HIV medications. Presiding over the U.S. District Court for the Eastern District of New York, Judge Ann M. Donnelly also denied the defendants’ motion to dismiss the case for…
Distributed control system supports CMO’s surge in drug production during the pandemic
In the early days of the COVID-19 pandemic, Thermo Fisher Scientific (NYSE:TMO) quickly expanded its manufacturing capacity at its Greenville, North Carolina plant to meet demand. The expansion involved adding a new production suite, safeguarding quality, and enabling sufficient production flexibility. During the expansion, the plant upgraded its existing Distributed Control System (DCS) to support…
Gilead identifies counterfeit versions of two of its HIV drugs
Gilead Sciences (NSDQ: GILD) has announced that it has identified tampered and counterfeit versions of its HIV drugs Biktarvy and Descovy in the U.S. supply chain. Biktarvy is a blockbuster drug cocktail, raking up $7.26 billion in sales last year. 2020 sales of Descovy were $478 million. Foster City, Calif.–based Gilead said that unauthorized distributors…
Pharma 50: Here’s how the world’s largest pharma companies are doing
The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data…
Injectable anti-HIV therapies could see strong growth
The market for injectable anti-HIV therapeutics will be worth $28 billion by 2029, according to projections from the analyst and consulting firm GlobalData. GlobalData valued the broader HIV therapeutics market at $22.9 billion in 2019 across the U.S., France, Germany, Italy, Spain, U.K. and Japan. While the overall market is growing at a low single-digit…
CVS teams up with U.S. government to administer COVID-19 antibody therapy
CVS Health (NYSE:CVS), the parent of the retail pharmacy chain CVS Pharmacy, Aetna and other brands, has committed to partnering with the Trump administration to administer Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab). The company will administer the intravenous therapy to high-risk patients in their homes or long-term care facilities. In the pilot program, CVS will administer 1,000…
Pfizer to make Gilead’s remdesivir COVID-19 treatment
Pfizer (NYSE:PFE) announced today that it entered into a multi-year agreement with Gilead Sciences (NSDQ:GILD) to manufacture and supply its antiviral remdesivir treatment. The investigational antiviral remdesivir will be manufactured by Pfizer under the agreement as the company becomes one of the multiple external manufacturing organizations supporting efforts to scale up the supply of the investigational…
Gilead licenses remdesivir production to 5 generic drugmakers
Gilead Sciences’ (NSDQ:GILD) said Tuesday that it has signed licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir, the experimental drug being used in the U.S. to treat COVID-19. The non-exclusive, voluntary agreements allow the companies — Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — to manufacture remdesivir for distribution in 127…